Leveraging Analytical and Bioprocess Platforms for Biological Product Development and Commercialization
INTERNATIONAL ALLIANCE FOR BIOLOGICAL STANDARDIZATION
INTERNATIONAL ALLIANCE FOR BIOLOGICAL STANDARDIZATION
  • HOME
  • REGISTER
  • CONFERENCE INFORMATION
    • Call for Posters
    • Scientific Committee
    • Confirmed Speakers
    • Scientific Agenda
    • Conference E-Book
    • Download The Flyer
    • Conclusions and Recommendations
    • Meeting Slides
    • Organizer
  • VENUE & HOTELS
    • Venue
  • SPONSORS
    • Conference Sponsors
    • Sponsorship information
  • ABOUT IABS
    • Contact Us
    • IABS Upcoming Conferences
    • IABS Website
Register

Leveraging Analytical and Bioprocess Platforms for
Biological Product Development and Commercialization

Brussels, Belgium
May 14-15, 2025

- a Hybrid Meeting - 

Scientific Committee

Sponsors

Download the e-book with Agenda, Biosketchs & Abstracts

Organized by

Upcoming conferences
Meeting Flyer
IABS Website

 Share news about 
 this conference with your network

Agenda

Speakers Abstracts

Upcoming conferences
Meeting Flyer
IABS Website

Objectives of the meeting

Platforming technologies are now widespread in biotechnology for both human and veterinary products. They have demonstrated their effectiveness and serve as powerful tools throughout cell line development, upstream and downstream operations, formulation development, and analytical testing. Platforms utilize prior knowledge and shared industry experiences to speed up the development of innovative medicines. Additionally, contract development and manufacturing companies (CDMOs) heavily utilize platforms to work across products to help clients bring innovative new medicines to the clinic.

However, there are no universal standards on how to create, justify and support platforms across the pharmaceutical industry and disciplines. Including platform information and the specific non-product level of detail in dossiers is key for regulatory agencies to evaluate a platform’s robustness and applicability using tools such as a risk-based assessments. Rationale and justification on how prior knowledge and platform data is suitable for the intended product is essential in a review.

This Workshop will explore the use of platform approaches and technologies in development and registration. It will include case studies demonstrating how prior knowledge for a platform is applied across products. The objective is to help developers and manufacturers work with health authorities to align expectations from Phase 1 development through commercialization. Additional topics covered will include creating, verifying, and maintaining platforms, their lifecycle, using them in regulatory submissions, and transitioning from first-in-clinic trials to commercial approval.

Scientific Committee

  • Shawn Novick, Chair
  • Tura Camilli, Amgen
  • Christopher Carl Frye, Eli Lilly & Company
  • Jean-François Dierick, GSK
  • Marcel Hoefnagel, MEB
  • Caroline Leveder, Sanofi
  • Mourad Mellal, Catalent
  • Nadine Ritter, Global Biotech Experts
  • Marc Verhagen, Sanofi

Organising Committee

  • Shawn Novick, IABS Chair
  • Madinina Cox, IABS Secretariat

IABS

Rue Mina-Audemars, 3
CH-1204 Geneva

Switzerland

CONTACT US

Phone: +33 4 87 77 18 01

Cell: +33 6 35 31 40 90

Email: iabs@iabs.org

ORGANIZER

International Alliance for Biological Standardization

HOME
REGISTER
SCIENTIFIC COMMITEE
SPEAKERS
VENUE
SPONSORS
IABS
CONTACT

© 2022 IABS - International Alliance for Biological Standardization